Metastatic Kidney Cancer: What to Ask

When kidney cancer has spread, the goal usually shifts from removing it to controlling it for as long as possible with the fewest costs to daily life. Several drug combinations now exist for that, and they differ from each other in ways that matter to how you feel, not just to survival curves.

The first useful question is not "what do I take." It is "what are you choosing between, and why that one for me."

Trials in this disease sort people into favorable, intermediate, and poor risk groups before comparing treatments. Some results apply only to certain groups.

Ask which risk group you fall into, what put you there, and whether the trial evidence behind the proposed drug came from your group.

Four drug pairs come up most often as first treatment for advanced clear cell kidney cancer, which is the histology these trials enrolled. Each has a published trial behind it. Non-clear-cell kidney cancers, and people who have already had systemic treatment, are a separate conversation. The trials ran separately, with different entry criteria and different lengths of follow-up, so the figures below sit side by side rather than in a ranking.

Nivolumab plus ipilimumab. A short run of the two drugs together, then nivolumab on its own. Both are infusions the unit prepares and gives; the number of doses and the gaps between them are set by your oncologist. The comparison trial enrolled 1,096 people, of whom 847 were intermediate or poor risk. In that group, the 18-month survival rate was 75%, against 60% for sunitinib.

Pembrolizumab plus axitinib. The trial enrolled 861 people with no previous systemic treatment. The 1-year survival rate was 90%, against 78% for sunitinib. Median progression-free survival was 15.1 months versus 11.1 months. Responses occurred in 59.3% versus 35.7%.

Pembrolizumab plus lenvatinib. The trial enrolled 1,609 people. The 2-year survival rate was 79.2%, against 70.4% for sunitinib. Median progression-free survival was 23.9 months versus 9.2 months. Responses occurred in 71.0% versus 36.1%, with complete responses in 16.1% versus 4.2%.

Avelumab plus axitinib. Among 560 people with PD-L1-positive disease, median progression-free survival was 13.8 months against 7.2 months for sunitinib. With less than a year of median follow-up, there was no significant difference in overall survival.

Cabozantinib alone is an option for intermediate or poor risk disease. In a trial of 157 people, side effects of some kind occurred in more than 95%, and grade 3 or 4 effects in 68% on cabozantinib and 65% on sunitinib.

Response rates look impressive. The cost line is where the combinations separate.

In the pembrolizumab plus lenvatinib trial, grade 3 or higher side effects hit 82.4% of that arm, against 71.8% on sunitinib. More telling, 37.2% stopped treatment because of side effects, against 14.4% on sunitinib. The most common severe problems were high blood pressure at 27.6%, diarrhea at 9.7%, and weight loss at 8.0%.

There is a counterweight worth knowing. Quality of life was measured in that trial with several instruments. People on pembrolizumab and lenvatinib had similar or less deterioration in quality of life and symptom scores over time than people on sunitinib.

In the pembrolizumab plus axitinib trial, grade 3 or higher side effects were closer: 75.8% versus 70.6%.

Questions that follow from this:

• What proportion of your patients on this combination stop it early?
• Which side effect is most likely to be the one that ends treatment for me?
• If I stop the targeted drug but keep the immunotherapy, is that a real option?

The primary tumor is a separate decision from the drugs.

NCI notes that when cancer is unresectable or has spread, several procedures can relieve symptoms caused by the primary tumor. These include tumor embolization, external beam radiation, and nephrectomy. Removing the kidney in this setting is called cytoreductive nephrectomy.

Worth asking:

• Is removing my primary tumor part of the plan, and if so, before or after drug treatment?
• Is the reason for removing it symptom relief, or something else?
• If we leave it in place, what would change that decision later?

Ask what will count as the treatment working. The answer is rarely "the tumor disappears."

Specific things to ask for:

• The measurement being tracked, and how much change counts as progression.
• The interval between scans, and whether it changes if things are stable.
• Whether a single growing spot would change the whole plan, or be treated on its own with radiation.

First-line choice is not the last choice. Kidney cancer has second-, third-, and fourth-line options, and the order shapes what stays available.

Two questions are worth asking at the start, not at the point of change:

• If this combination stops working, what would you offer next?
• Does starting with this one rule anything out later?

The answer often turns on drug class. Most first-line combinations pair an immune checkpoint inhibitor with a drug that blocks blood vessel growth. It is tempting to assume that when one of those stops working the other class is still untapped, but which second-line option has evidence behind it depends on the exact regimen you had and how it failed. Ask your oncologist what the next line would be in your case.

Palliative care is symptom and stress management delivered at the same time as cancer treatment. It is not a substitute for it, and it does not signal a change in goals. Asking for a referral at the first visit is a reasonable request.

Kidney cancer spreads most often to the lungs, bones, liver, and brain. Ask which sites your imaging covers and how often. Bone spread in particular has its own treatments, and a new persistent bone pain is worth reporting the same week rather than at the next scheduled visit.

A second opinion is most useful here when the choice is between two reasonable combinations, when a clinical trial exists at another center, or when a rarer cell type is involved.

Ask whether your tumor's pathology has been reviewed for cell type and sarcomatoid features. Ask whether your case has been discussed at a tumor board. Ask whether joining a trial later remains possible once first-line treatment starts, because for some studies it does not.

For how stage is assigned and what molecular testing adds, see cancer staging and biomarker testing. For the disease overview, see kidney cancer.

• Call 911 or go to an emergency department if you have new weakness or numbness in your legs, trouble walking, or you lose control of your bladder or bowel, especially alongside back pain. Bone spread pressing on the spinal cord is treated as an emergency, because delay costs function that does not come back. Go too if you are passing heavy blood or clots in your urine with dizziness or fainting, if you cough up blood, or if belly pain is sudden, severe and your abdomen feels hard.
• Call your care team the same day if you record 100.4°F (38°C) or higher, or shake with chills. On a checkpoint drug a fever can be an infection or the immune system attacking healthy tissue, and separating the two needs blood tests rather than waiting it out. On nivolumab, ipilimumab or pembrolizumab, call the same day for diarrhea several times more often than usual, blood or mucus in your stool, or a new cough or breathlessness. On a tyrosine kinase inhibitor such as axitinib, cabozantinib or lenvatinib, call the same day for a bad headache with home blood pressure readings well above your normal. Call the same day too if you are passing much less urine, or have new pain in your side or back.
• Chemotherapy or another marrow-suppressing drug changes that. Then 100.4°F (38°C) is a medical emergency, not a same-day call (CDC). Contact the team immediately whatever the hour, and go to an emergency department if the line does not get you a person.
• Call your care team within a day or two if bone pain is new and persistent, particularly if it wakes you at night. Do the same for sore, red or blistered palms and soles, for a new rash, and for feeling unusually tired, cold or slowed down, which can mean the thyroid has been affected. Report new yellowing of the eyes or skin in the same window.

• National Cancer Institute, Renal Cell Cancer Treatment PDQ, health professional version, updated May 13, 2025; accessed August 6, 2026
• National Cancer Institute, Immune Checkpoint Inhibitors; accessed August 11, 2026
• National Cancer Institute, Infection and Neutropenia During Cancer Treatment; accessed August 11, 2026
• StatPearls via NCBI Bookshelf, Spinal Cord Compression; accessed August 11, 2026